...
【24h】

Inhibition of Type 1 Diabetes Development by Vitamin D Receptoi Agonists

机译:抑制1型糖尿病的发展维生素D Receptoi受体激动剂

获取原文
获取原文并翻译 | 示例
           

摘要

Vitamin D receptor (VDR) agonists are well-known for their capacity to control calcium metabolism and to regulate growth and differentiation of many cell types. More recently, it has become clear that VDR agonists possess exquisite immunoregulatory properties, mostly by targeting dendritic cells and T cells. These properties have been exploited in the treatment of several Thl-mediated experimental autoimmune diseases, and a considerable body of work documents their beneficial effects in inhibiting the development of type 1 diabetes (T1D), a chronic-progressive autoimmune disease leading to the destruction of insulin-producing pancreatic beta cells. This review analyzes the capacity of different VDR agonists to inhibit spontaneous T1D development in the non-obese diabetic (NOD) mouse, and shows that lalpha,25-(OH)_2-16,2.3Z-diene-26,27-hexafluoro-19-nor D_3 (compound 6) is the most effective analog, among those tested, in delaying and reducing disease progression. Identified mechanisms of action underlying the efficacy of this VDR agonist in inhibiting T1D development in the NOD mouse are also reviewed.
机译:维生素D受体(VDR)受体激动剂是众所周知的他们的能力控制钙代谢和调节生长和分化许多细胞类型。清楚,VDR受体激动剂具有细腻免疫调节特性,主要是通过定位树突细胞和T细胞。利用治疗几个呢Thl-mediated实验性自身免疫性疾病,和一个相当大的工作文档抑制发展的有利影响1型糖尿病(近年来),chronic-progressive自身免疫性疾病导致的破坏产生胰岛素的胰腺β细胞。回顾分析不同船舶的能力受体激动剂抑制自发近年来发展在非肥胖糖尿病(NOD)小鼠,并显示那

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号